At Sano, we’re continuously upgrading our platform and expanding our services to ensure we’re keeping up with the pace of precision medicine. Trials are difficult to manage, and genetic or biomarker testing adds further complexity. Adding a single test often means finding new labs, training new staff, updating protocols, and coordinating multiple vendors. This results in longer timelines, higher costs, and increased risk of participant drop-out.
We believe science shouldn't be held back by logistics. That's why we’ve introduced a broader set of testing capabilities that make it easier to design, run, and scale decentralized studies.
Our expanded options now include:
- At-home antibody testing: Fast, decentralized eligibility checks using small blood samples collected without a clinic visit (currently available for research use only).
- Polygenic Risk Scores (PRS): Pre-screening tools that enable smarter, more targeted recruitment based on genetic predispositions.
- Repeat expansion sequencing: Specialized testing for various conditions, seamlessly combined with other assays in a single protocol.
In this product feature, we highlight the new ways we’re making it easier than ever to design, run, and scale decentralized studies to reach more people and generate richer data.
Minimize participant barriers
Decentralized, at-home collection has always been part of Sano’s DNA, but until recently, we focused on genetic testing via saliva and buccal swab kits. Now, we’re going further, adding new technologies and workflows that make it possible to collect a wider range of samples from the comfort of home, without compromising quality or compliance.
One example is our partnership with Tasso, which enables participants to collect a small blood sample themselves, removing the need for a clinic visit and reducing unnecessary labor for healthcare professionals. This opens the door for antibody testing to be done entirely at home. At present, this testing has not been clinically validated and is available only for research use.
This allows sponsors to:
- Detect trial eligibility without coordinating site appointments.
- Screen larger, more diverse populations at lower cost.
- Reduce the risk of delays from missed site visits or participant scheduling issues.
For participants, at-home sampling creates a faster, easier, and more inclusive experience. Without the need to travel or take time off work to provide a sample, the financial burden is lowered. Everything can be done in the comfort of their own home, reducing stress and inconvenience while maintaining clinical-grade data quality.
Compared with traditional approaches, which often require scheduling a phlebotomist appointment for a blood draw, which can be intimidating or unpleasant for some, the Tasso device offers an innovative alternative. With a press of a button on an upper-arm patch, blood is drawn quickly and with minimal pain, making participation far less daunting.
The result is higher enrollment, lower dropout rates, and a more representative participant pool – all while maintaining clinical-grade data quality.
Screen and identify eligible participants faster
Early, accurate screening is essential for recruitment success. Our expanded testing options mean you can find the right participants quickly without relying solely on in-clinic visits or slow lab pipelines.
Antibody testing from at-home blood samples makes it possible to rapidly confirm eligibility or measure immune response in ongoing trials. Integrating PRS further strengthens this approach by incorporating a broader set of genetic factors, enabling more accurate pre-screening for predispositions. This allows sponsors to target recruitment with greater precision and enrich study populations in ways that single-variant testing alone cannot achieve.
This means that sponsors can shorten recruitment timelines, focus on the right participants sooner, and reduce the number of ineligible participants in downstream stages, saving both time and budget.
Unlock new condition areas
Many neurological and rare diseases require specialized testing not supported by standard genetic workflows. With our new capabilities, sponsors can include repeat expansion sequencing, a vital tool for research into conditions like Huntington’s, Parkinson’s, ALS, and other neurodegenerative diseases. In parallel, we can combine repeat expansions with whole genome sequencing (WGS) or other assays in a single protocol, without creating separate operational tracks.
By removing these operational barriers, we’re enabling more comprehensive disease profiling and making it possible to run complex, multi-assay studies in a single streamlined process.
Deliver results that matter
We understand that not all studies require the same level of reporting of participant results. Accordingly, we now offer a flexible framework that supports both clinical and research contexts and allows for better alignment with budgets.
We also collaborate with partners to support clinical-grade testing for medically actionable results, delivered in partnership with accredited labs and supported by genetic counseling networks. On the other hand, we recommend research-use-only testing for exploratory or early-stage studies, where speed, cost-effectiveness, and agility are the priority.
This means you can meet scientific and regulatory needs without having to choose between speed and compliance.
Everything connected in one platform
All of these new capabilities are powered by the same infrastructure that powers our biomarker testing and logistics, which provides the following features:
- Multiple sample types and tests supported within a single study.
- Full tracking from order to results through KitLink, our end-to-end biomarker testing coordination and logistics tool.
- Integrated lab and logistics network or the option to bring your own.
- Participant-friendly reporting for every result type.
This means you can expand your study without building new systems or creating operational silos.
Focus on meaningful insights
Our expanded capabilities ensure that you can focus on generating meaningful insights while we handle the operational complexities. We make it easier to keep participants engaged and motivated throughout the study, so you can recruit faster, expand your reach to include those who might otherwise be excluded due to location, mobility, or time constraints, and deliver results with confidence.
Whether you’re exploring new biomarkers, adding targeted follow-up testing, or entering a new therapeutic area, Sano can help you deliver at-home testing that scales without adding complexity.
Let’s make your next study faster, more inclusive, and more flexible. Book a demo with our team to explore what’s possible.